These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21969515)

  • 1. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
    Shepherd FA
    J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
    de Marinis F; Ardizzoni A; Fontanini G; Grossi F; Cappuzzo F; Novello S; Santo A; Lorusso V; Cortinovis D; Iurlaro M; Galetta D; Gridelli C;
    Clin Lung Cancer; 2014 Sep; 15(5):338-45.e1. PubMed ID: 24925809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
    Lee CN; Chen HY; Liu HE
    J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
    Ostoros G; Döme B; Strausz J; Tímár J
    Magy Onkol; 2010 Jun; 54(2):137-43. PubMed ID: 20576590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
    Toffalorio F; de Marinis F; Conforti F; Spitaleri G; Catania C; Noberasco C; Lazzari C; Vecchio F; Stufano V; Barberis M; De Pas T
    J Thorac Oncol; 2015 Feb; 10(2):392-6. PubMed ID: 25611230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L; Li Y; Zhang SB; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract]   [Full Text] [Related]  

  • 12. Are all KRAS mutations created equal?
    Stinchcombe TE; Der CJ
    Lancet Oncol; 2011 Aug; 12(8):717-8. PubMed ID: 21782508
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
    Ayoola A; Barochia A; Belani K; Belani CP
    Cancer Invest; 2012 Jun; 30(5):433-46. PubMed ID: 22571344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS;
    J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
    Gottschling S; Herpel E; Eberhardt WE; Heigener DF; Fischer JR; Köhne CH; Kortsik C; Kuhnt T; Muley T; Meister M; Bischoff HG; Klein P; Moldenhauer I; Schnabel PA; Thomas M; Penzel R
    Lung Cancer; 2012 Jul; 77(1):183-91. PubMed ID: 22483783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
    Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
    Ferté C; Besse B; Dansin E; Parent F; Buisine MP; Copin MC; Penel N; Soria JC
    Ann Oncol; 2010 Jun; 21(6):1385-1387. PubMed ID: 20501506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.